TITRE |
Étude de phase I du topotécan à dose métronomique et pazopanib chez les enfants et adolescents avec une tumeur solide récurrente ou réfractaire incluant les tumeurs du système nerveux central
|
PROTOCOLE ID |
IND.217 (TOPAZ) |
CLINICAL TRIAL.gov ID |
NCT02303028 |
TYPE(S) DE CANCER |
Pédiatrique divers |
PHASE |
Phase I |
TYPE D'ÉTUDE |
|
INSTITUTION |
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
3175 Chemin de la Côte Sainte-Catherine
(514) 345-4931
|
VILLE |
Montréal
|
INVESTIGATEUR(RICE) PRINCIPAL(E) |
Monia Marzouki
|
COORDONATEUR(RICE) |
Linda Hershon linda.hershon@recherche-ste-justine.qc.ca 514-345-4931 poste 5899
|
STATUT |
Actif en recrutement
|
CRITÈRES D'ÉLIGIBILITÉ |
(EN)
-
Disease: Part 1-Relapsed or refractory solid tumours including CNS tumours; Part 2A-Neuroblastoma, Part 2B Rhabdomyosarcoma
-
Measurable or evaluable disease
-
No known curative therapy, or therapy proven to prolong survival with an acceptable QOL
-
Organ Function Criteria
-
Peripheral ANC ≥ 1,500/μL; Plt ≥ 100,000/ and Hb ≥ 80 g/L (RBC transfusion permitted)
-
Measured creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2, OR a serum creatinine based on age/gender that meets the criteria outlined in the protocol
-
Urinalysis negative for protein, urine protein:creatinine ratio of ≤ 1, OR a 24-hour urine protein < 1000 mg/dL
-
<Gr.1 abnormalities of K, Ca (confirmed by ionized Ca),Mg or Ph (supplementation allowed)
-
Total serum bilirubin ≤ 1.5xULN for age
-
SGPT (ALT) ≤ 2.5 x ULN and SGOT (AST) ≤ 2.5 x ULN
-
Serum albumin ≥ 20 g/L
-
Adequate systolic ventricular function (LVSF≥ 27% or LVEF ≥ 50%)
-
QTc measured by ECG must be < 450 msec.
-
No history of MI, severe or unstable angina, peripheral vascular disease, or familial QTc prolongation
-
Blood pressure ≤ 95th percentile for age, height, gender AND one of:
-
No current anti-hypertensive therapy, OR on stable doses of no more than one anti-hypertensive medication
-
Subjects with known history of seizures must have well-controlled seizures and not receiving enzyme-inducing anti-convulsants
-
INR ≤ 1.2 and PTT ≤ 1.2xULN
-
Prior Therapy
-
Myelosuppressive chemo must not have been given within 3 weeks of study enrolment (6 weeks if nitrosourea)
-
At least 7 days must have elapsed since completion of therapy with a growth factor that supports platelet or white cell number or function. At least 14 days must have elapsed after receiving pegfilgrastim.
-
Biologic anti-neoplastic agent (including VEGF-blocking TKI) must not have been administered within 7 days of study enrolment
-
At least 3 half lives of the monoclonal antibody must have elapsed since the last dose administered
-
≥ 2 weeks must have elapsed since local palliative XRT (small port); > 13 weeks since prior total body irradiation (TBI), craniospinal XRT or > 50% radiation of pelvis; or > 6 weeks if other substantial bone marrow irradiation
-
≥ 8 weeks must have elapsed since MIBG therapy for neuroblastoma
-
At least 60 days must have elapsed from autologous or allogeneic stem cell transplant with no signs of GVHD.
-
At least 28 days from major surgery and wounds must be healed. At least 7 days from open and/or core biopsy.
-
Ability to take liquid medication by mouth
|
CRITÈRES D'EXCLUSION |
(EN)
|